Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
Status:
Completed
Trial end date:
2018-09-27
Target enrollment:
Participant gender:
Summary
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is
exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may
be an effective treatment for laryngeal cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of laser light therapy
when given together with HPPH in treating patients with dysplasia, cancer in situ, or
invasive cancer of the larynx.